Novartis names new pharma unit head

Friday, 07. June 2019 07:41

Novartis announced on Friday that it appointed Marie-France Tschudin the new president of the company's drug unit Novartis Pharmaceuticals with immediate effect. Tschudin will replace Paul Hudson who is leaving the Swiss pharmaceutical giant to take the position of the CEO at rival firm Sanofi.

"I am pleased that Marie-France Tschudin is ready to take over from Paul Hudson to further grow the business and lead the expected upcoming launches of our transformative medicines. Marie-France has a strong record of accomplishments in driving commercial excellence and a culture of inclusiveness and integrity founded on her exemplary commitment to patients and customers. She has always been highly respected by people working with her and will bring new and diverse perspectives to our executive leadership team," Novartis CEO Vas Narasimhan stated.

Tschudin has worked for Novartis since 2017 and served as the head of Novartis-owned Advanced Accelerator Applications (AAA), as well as a member of the Novartis Pharmaceuticals Executive Committee and Head of Novartis Pharmaceuticals, Region Europe.

Related Links: Novartis AG
Breaking the News / NP